Tzanetakos C, et al. – The cost–effectiveness of certolizumab pegol (CZP) was examined as add–on therapy to methotrexate (MTX) versus etanercept, adalimumab, or golimumab in patients with moderate–to–severe active rheumatoid arthritis (RA) not responding to the conventional synthetic disease–modifying anti–rheumatic drugs (csDMARDs). The evaluation approved that CZP+MTX was a cost–effective alternative over Etanercept+MTX and a dominant option over Adalimumab+MTX and Golimumab+MTX for management of RA.